The shingles vaccine (Shingrix) provides strong protection for at least 10 years, with the most recent clinical data showing it still works well into the eleventh year after vaccination. Protection starts high, above 90% in the first few years, and gradually decreases but remains meaningful a decade later. No booster dose is currently recommended.
Protection Year by Year
The best data on how long Shingrix lasts comes from a long-term follow-up of the original clinical trials, tracking participants for over a decade. At year four after vaccination, efficacy against shingles was about 90%. By year seven, it was still above 83%. At the ten-year mark, protection had dropped to roughly 73%.
The final analysis of that long-term study, published in The Lancet’s eClinicalMedicine in 2025, extended the picture even further. Over the full follow-up period, vaccine efficacy was 87.7% for adults 50 and older, and in the eleventh year specifically, protection held at 82%. That’s a reassuring number, suggesting the vaccine’s decline isn’t a steep cliff but a gradual slope.
How Age Affects Duration
People often wonder whether the vaccine wears off faster if you’re older when you get it. The CDC notes that in adults 70 and older with healthy immune systems, Shingrix immunity remained high for at least seven years. The clinical trial data showing protection into year 11 included adults across age groups starting at 50, so the overall numbers reflect a mix of ages. While older adults generally mount slightly weaker immune responses to any vaccine, the protection from Shingrix has proven durable even in this group.
Why Protection Lasts So Long
Shingrix works differently from many vaccines. It’s a non-live vaccine that contains a single protein from the varicella-zoster virus, the same virus that causes chickenpox and later reactivates as shingles. What makes Shingrix unusually effective is its adjuvant, a booster ingredient that triggers a strong response from both antibodies and T cells.
T cells are the key to long-term shingles prevention. After chickenpox, the virus hides in nerve cells for decades. Your immune system keeps it dormant primarily through specialized T cells that patrol for signs of reactivation. As you age, these T cells naturally decline, which is why shingles risk increases after 50. Shingrix essentially retrains and expands your supply of these virus-specific T cells, and the strong adjuvant helps create long-lasting memory cells that persist for years.
How It Compares to the Old Vaccine
The previous shingles vaccine, Zostavax, was a live vaccine that has since been discontinued. Its protection faded significantly after about five years. Shingrix roughly doubles that durability while also providing stronger protection at every time point. If you previously received Zostavax, you can still get Shingrix to improve your protection.
Booster Doses and What’s Next
As of 2025, the CDC does not recommend a booster dose of Shingrix. The two-dose series, with shots spaced two to six months apart, is the complete regimen. Studies on long-term immunity are still ongoing, and recommendations could change as more data accumulates beyond the current 11-year window. But with efficacy still above 80% at year 11, there’s no urgency for a third dose.
If more than six months pass between your first and second dose, you don’t need to start over. Just get the second dose as soon as you can. The CDC recommends staying within the two-to-six-month window when possible, but a delayed second dose still counts.
Protection for Immunocompromised Adults
Adults 19 and older with weakened immune systems, whether from medical conditions or treatments like chemotherapy, are eligible for Shingrix and can receive their two doses on a shorter schedule (one to two months apart instead of two to six). However, how long the vaccine protects this group is less clear. Studies on duration of immunity in immunocompromised people are still underway, and no separate booster recommendation exists for them yet. Because their immune systems may not sustain the same long-term response, this is an area where future guidance could differ from the general population.